Using ML algorithms, sensitivity of ewECG is suitable for application as a screening test for SBHF in apparent SAHF. Our data suggest ewECG could reduce the number of echocardiograms performed as part of a HF population screening program by 18-25%.
HeartSciences’ AI-ECG products are currently in development and not commercially available in the United States.
wavECG and wavEKG are trademarks of HeartSciences.
MV-WBSTE-002 Rev A
